BMO Capital Highlights Privia Health Group’s Strong Growth Potential and Differentiated Risk Management in Value-Based Care
I'm PortAI, I can summarize articles.
BMO Capital has initiated a Buy rating for Privia Health Group (PRVA), citing its strong long-term earnings growth potential and effective value-based care approach. The firm highlights Privia's stable earnings, impressive free cash flow, and significant expansion opportunities, projecting over 20% EBITDA growth in the next two years. Privia's unique risk management strategy, which involves sharing risk with payers and providers, is expected to enhance profitability. Canaccord Genuity also reiterated a Buy rating with a $34.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments